companies / endeavorbio-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-20 json
| total_raised | 132,500,000132.5M | ○ |
|---|---|---|
| founded | null | |
| hq | San Diego CA | |
| industry | unknown | |
| stage | series-b+ |
Endeavor BioMedicines is a clinical-stage biotechnology company developing medicines for life-threatening fibrotic and oncology diseases. It serves patients with conditions such as idiopathic pulmonary fibrosis through taladegib, a Hedgehog pathway inhibitor. Its pipeline also includes ENV-501, an antibody-drug conjugate targeting fibrosis.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-04-01 | series-c | 132,500,000132.5M | null | ○ |
| investor | src |
|---|---|
| GV | ○ |
| fact | status | src |
|---|---|---|
| Series C, $132.5M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-27latest_round: series-c, $132.5M, 2024-04-01, lead: gv → series-c, $132.5M, 2024-04-01, lead: null, ○ 2026-05-20 | latest_round | series-c, $132.5M, 2024-04-01, lead: gv → series-c, $132.5M, 2024-04-01, lead: null | ○ 2026-05-20 |
Records begin 2026-09-24. all_changes